OBJECTIVE:To compare the efficacy of atorvastatin and rosuvastatin in treatment of elderly coronary heart disease and(or) type 2 diabetes.METHODS:130 patients with elderly coronary heart disease and (or) type 2 diabetes admitted into the geriatric department of the First People's Hospital of Guangzhou Medical University from Jan . 2014 to Mar.2015 were selected to be divided into group A and group B via the random number table , with 65 cases in each.Patients in group A were treated with atorvastatin , the dose of 10-40 mg/d and the average dose of 20 mg/d;and group B received rosuvastatin , the dose of 5-20 mg/d and the average dose of 7.6 mg/d;the treatment course was 6 months, and changes of blood lipid level in two group of patients were observed .RESULTS: After treatment , the total cholesterol ( TC ) , triglyceride ( TG ) , low density lipoprotein cholesterin ( LDL-C ) , high density lipoprotein cholesterol ( HDL-C) of two group of patients were significantly decreased compared with before treatment .The TC and LDL-C of group A after treatment was (3.22 ±0.17) and (1.56 ±0.11) mmol/L, significantly higher than that of before treatment ( 3.73 ±0.15 ) and ( 1.97 ±0.12 ) mmol/L; meanwhile , the TC and LDL-C of group B after treatment was ( 3.21 ±0.19 ) and ( 1.60 ±0.11 ) mmol/L, significantly higher than that of before treatment (3.84 ±0.21) and (1.98 ±0.12) mmol/L, with statistically significant difference (P0.05) .CONCLUSIONS:Atovastatin and rosuvastain can effectively decrease the TC and LDL-C of patients with elderly coronary heart disease ( or) type 2 diabetes, yet the liver and kidney function of patients and adverse drug reactions should be closely monitored during the treatment process .%目的：比较阿托伐他汀和瑞舒伐他汀治疗高龄冠心病和（或）2型糖尿病患者的疗效。方法：选择2014年1月—2015年3月在广州市第一人民医院老年科住院的高龄冠心病和（或）2型糖尿病患者130例作为研究对象，按随机数字表法分为2组各65例。 A组患者应用阿托伐他汀进行治疗，服药剂量为10～40 mg／d，平均剂量为20 mg／d；B组患者应用瑞舒伐他汀进行治疗，服药剂量为5～20 mg／d，平均剂量为7.6 mg／d，2组患者疗程均为6个月，观察2组患者的血脂水平变化情况。结果：治疗后，2组患者的总胆固醇（ TC）、甘油三脂（ TG）、低密度脂蛋白胆固醇（ LDL-C）、高密度脂蛋白胆固醇（ HDL-C）均较治疗前有所改善。其中，A组患者TC、LDL-C为（3.22±0.17）、（1.56±0.11） mmol／L，均明显优于治疗前的（3.73±0.15）、（1.97±0.12） mmol／L；B组患者的TC、LDL-C为（3.21±0.19）、（1.60±0.11） mmol／L，均明显优于治疗前的（3.84±0.21）、（1.98±0.12） mmol／L，差异均有统计学意义（ P＜0.05）。治疗期间，A组1例患者出现急性心肌梗死，2例出现转氨酶升高；B组2例患者出现急性心肌梗死，2例出现转氨酶升高，2组的差异无统计学意义（ P＞0.05）。结论：阿托伐他汀和瑞舒伐他汀均能够有效降低高龄冠心病和（或）2型糖尿病患者的TC和LDL-C，但在治疗过程中需密切监测患者的肝、肾功能及不良反应发生情况。
展开▼
